Cytokinetics Inc vs Tapestry, Inc. — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Tapestry, Inc. trades at $161.95 (market cap $33.29B). The key difference: Tapestry, Inc. is far larger — about 3.1× Cytokinetics Inc's market cap, and Tapestry, Inc. pays a 0.97% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TPR | |
|---|---|---|
Market Cap | $10.78B | $33.29B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $164.78 |
52-Week Low | $34.31 | $95.69 |
Enterprise Value | $10.88B | $36.15B |
Dividend Yield | — | 0.97% |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
TPR trades at $162.36, up 0.22% today, and is near its 52-week high with strong bullish technical signals. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Recent news highlights AI integration and brand momentum, while analyst consensus is strongly bullish with a $190.33 price target.
Outlook remains positive driven by earnings growth and strategic initiatives, but risks include high valuation multiples and volatile cash flows. The stock offers upside to analyst targets but faces margin pressure and competitive challenges in the retail sector.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →